Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Lee, AW; Liu, K; Lhomme, E; Blie, J; McCullough, J; Onorato, MT; Connor, L; Simon, JK; Dubey, S; VanRheenen, S; Deutsch, J; Owens, A; Morgan, A; Welebob, C; Hyatt, D; Nair, S; Hamzé, B; Guindo, O; Sow, SO; Beavogui, AH; Leigh, B; Samai, M; Akoo, P; Serry-Bangura, A; Fleck, S; Secka, F; Lowe, B; Watson-Jones, D; Roy, C; Hensley, LE; Kieh, M; Coller, BAG

Coller, BAG (通讯作者)，Merck & Co Inc, 126 E Lincoln Ave, Rahway, NJ 07065 USA.

CLINICAL INFECTIOUS DISEASES, 2023; ():

Abstract

Background The rVSV Delta G-ZEBOV-GP vaccine (ERVEBO (R)) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索